Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 62 results
Filters: First Letter Of Title is I  [Clear All Filters]
Found 62 results.


Carlton-Smith C, Holmes JA, Naggie S, et al. "IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR." J. Viral Hepat.. 2017.
Neto MF, Butzler MA, Reed JL, et al. "Immiscible phase filter extraction and equivalent amplification of genotypes 1-6 of hepatitis C RNA: The building blocks for point-of-care diagnosis." J. Virol. Methods. 2017;248:107-115.
Coban H, Robertson K, Smurzynski M, et al. "Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen." AIDS. 2017;31(11):1565-1571.
Park YJeong, Etemad B, Ahmed H, et al. "Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption." Pathog Immun. 2017;2(3):431-445.
Badal-Faesen S, Firnhaber C, Kendall MA, et al. "Impact of Larger Sputum Volume on XpertMTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis." J Clin Med. 2017;6(8).
Parker RA, Rabideau DJ, Sax PE, et al. "Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study." Clin. Infect. Dis.. 2017;64(11):1612-1614.
Erlandson KM, Kitch D, C Wester W, et al. "The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection." Clin. Infect. Dis.. 2017;65(12):2042-2049.
Venuto CS, Lim J, Messing S, Hunt PW, McComsey GA, Morse GD. "Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s." Antivir. Ther. (Lond.). 2017.
Erlandson KM, Fiorillo SP, Cardoso SWagner, et al. "Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation." AIDS Res. Hum. Retroviruses. 2017;33(9):929-934.


Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ. "Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment." HIV Clin Trials. 2013;14(2):61-7.
Lok JJ, Hunt PW, Collier AC, et al. "The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy." AIDS. 2013;27(13):2101-10.
Li JZ, Paredes R, Ribaudo HJ, et al. "Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure." J. Infect. Dis.. 2013;207(6):893-7.
Ribaudo HJ, Daar ES, Tierney C, et al. "Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202." J. Infect. Dis.. 2013;207(3):420-5.
Godfrey CC, Michelow PM, Godard M, et al. "Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks." Am. J. Clin. Pathol.. 2013;140(6):881-9.
Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. "In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use." Am. J. Clin. Nutr.. 2013;98(2):423-9.
Vandergeeten C, Fromentin R, DaFonseca S, et al. "Interleukin-7 promotes HIV persistence during antiretroviral therapy." Blood. 2013;121(21):4321-9.
Hochreiter J, Lapham J, Wong-Staal F, et al. "ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection." Antivir. Ther. (Lond.). 2013;18(3):329-36.